Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR8943009

—

5af43693-1d4a-57a8-a99f-5eaaad222f73

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MTORC1_SIGNALING+0.510
  • E2F_TARGETS+0.500
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • HYPOXIA+0.500
  • MYC_TARGETS_V1+0.480
  • MYC_TARGETS_V2+0.460
  • GLYCOLYSIS+0.450
  • ANGIOGENESIS+0.410
  • CHOLESTEROL_HOMEOSTASIS+0.400
  • G2M_CHECKPOINT+0.400

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.600
  • INTERFERON_GAMMA_RESPONSE-0.500
  • ALLOGRAFT_REJECTION-0.280
  • IL6_JAK_STAT3_SIGNALING-0.260
  • INFLAMMATORY_RESPONSE-0.070
  • COMPLEMENT-0.040
  • IL2_STAT5_SIGNALING-0.020
  • KRAS_SIGNALING_DN-0.020
  • WNT_BETA_CATENIN_SIGNALING-0.020
  • BILE_ACID_METABOLISM-0.010

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-52-7810-01A-11R-2125-07
lung-landscapes@6
—cohortSQ10.898
2TCGA-CR-5247-01A-01R-2016-07
head-neck@1
——0.892
3MNG1297
mng-umap@100
——0.878
4SRR8526723
lung-landscapes@6
—cohortA10.859
5SRR35579803
breast-umap@18
—E0.847
6TCGA-E9-A1N6-01A-11R-A144-07
breast-umap@18
—C0.843
7C3L-02130
lung-landscapes@6
—cohortSQ10.839
8TCGA-22-5482-01A-01R-1635-07
lung-landscapes@6
—cohortSQ20.834
9TCGA-92-7341-01A-31R-2045-07
lung-landscapes@6
—cohortSQ20.833
10TCGA-OR-A5JP-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.832

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 40 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MTORC1_SIGNALING0.510Inavolisib— uncovered
E2F_TARGETS0.500Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
HYPOXIA0.500Idelalisib— uncovered
MYC_TARGETS_V10.480Inavolisib— uncovered
MYC_TARGETS_V20.460Idelalisib— uncovered
GLYCOLYSIS0.450Inavolisib— uncovered
ANGIOGENESIS0.410Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.400Remibrutinib— uncovered
G2M_CHECKPOINT0.400Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
NOTCH_SIGNALING0.390Inavolisib— uncovered
ADIPOGENESIS0.370Inavolisib— uncovered
COAGULATION0.370Binimetinib— uncovered
ESTROGEN_RESPONSE_LATE0.360Idelalisib— uncovered
UV_RESPONSE_UP0.340Idelalisib— uncovered
HEDGEHOG_SIGNALING0.330Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.330Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.320Inavolisib— uncovered
TGF_BETA_SIGNALING0.290Inavolisib— uncovered